Denosumab monotherapy versus bisphosphonate switching in breast cancer bone metastases: A real-world cohort study on skeletal events and safety. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial At a preplanned efficacy ...
Abemaciclib (from Lilly) is heading to become the third of a new class of drugs for use in breast cancer — the cyclin-dependent kinase (CDK) 4/6 inhibitors. The US Food and Drug Administration (FDA) ...
The MONARCH-3 trial is a phase 3, randomized, double-blinded, placebo-controlled trial that evaluated the use of abemaciclib alone and in combination with a non-steroidal aromatase inhibitor (eg, ...
Please provide your email address to receive an email when new articles are posted on . Results from a phase 2 study showed that abemaciclib in combination with letrozole shrunk or stabilized tumors ...
Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Imlunestrant alone or as part of combination therapy extended PFS for certain patients with ...
The anti-cancer drug abemaciclib (also known as Vernezio) has been added to the Australian Pharmaceutical Benefits Scheme (PBS) to treat certain types of breast cancer. This significantly reduces the ...
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the ...
Hosted on MSN
Abemaciclib + Endocrine Therapy Improves Survival in HR-Positive, HER2-Negative Early Breast Cancer
THURSDAY, Oct. 23, 2025 (HealthDay News) -- For patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive, high-risk early breast cancer (EBC), ...
INDIANAPOLIS, Oct. 13, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), in combination with endocrine therapy ...
The US Food and Drug Administration (FDA) has expanded the indication for adjuvant abemaciclib (Verzenio) in combination with endocrine therapy for patients with hormone receptor (HR)–positive, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results